Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Gynecologic Oncology

Clinical research in ovarian cancer, fallopian tube cancer, and primary peritoneal cancer includes advanced, recurrent, platinum-resistant, and HRD-guided treatment strategies, as well as studies in patients with disease involving the pelvis and peritoneum.

  • Advanced and recurrent ovarian malignancies
  • Platinum-resistant disease
  • Pelvic exenteration in gynecologic cancer
  • Pre-neoplastic vulvar and cervical lesions
  • Vulvar Paget’s disease

Interest also extends to electrochemotherapy, pembrolizumab-based approaches, and biomarker-informed management of HPV-related and invasive gynecologic lesions.

Genitourinary and Renal Cancer

The sponsor supports studies in metastatic castration-resistant prostate cancer, metastatic renal cell carcinoma, urothelial cancer, and muscle-invasive bladder cancer, with attention to molecular features that may guide treatment selection.

  • Prostate cancer with BRCA-negative or unknown status
  • Renal cell carcinoma
  • Urothelial carcinoma
  • Bladder cancer
  • DDR gene alterations

Research activity also includes immunotherapy combinations, platinum sensitivity, and surgical oncology questions in advanced urinary tract malignancies.

Thoracic, Colorectal, and Melanoma Oncology

Ongoing work covers EGFR-mutant non-small cell lung cancer, metastatic colorectal cancer with BRAF V600E mutation, and metastatic uveal melanoma, reflecting a strong focus on molecularly defined solid tumors.

  • EGFR-mutant NSCLC
  • BRAF V600E-mutated metastatic colorectal cancer
  • Uveal melanoma
  • HER2-positive breast cancer
  • Targeted therapy and immunotherapy

These studies include biomarker-driven treatment in TP53-defined lung cancer and resistance monitoring in HER2-directed therapy.

Autoimmune, Neuromuscular, and Neuro-Oncology Disorders

Non-oncologic research includes generalized myasthenia gravis, refractory systemic autoimmune diseases, connective tissue disease-associated interstitial lung disease, and optic pathway glioma in children and young adults.

  • Myasthenia gravis
  • Systemic autoimmune disease
  • Connective tissue disease-associated interstitial lung disease
  • Optic pathway glioma
  • Neuroimmunology

Additional interest is shown in CAR T-cell therapy, rituximab, and visual function preservation in pediatric neuro-oncology.

Cardiometabolic and Psychiatric Research

The portfolio also includes myocardial infarction with non-obstructive coronary arteries, treatment-resistant depression, obesity, and type 2 diabetes, indicating activity across cardiovascular, metabolic, and mental health domains.

  • MINOCA
  • Treatment-resistant depression
  • Obesity
  • Type 2 diabetes
  • Precision medicine

Research in this area includes biomarker-based phenotyping, brain imaging of neurotransporter function, and treatment response assessment in metabolic disease.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on Tebentafusp and Liver Radiotherapy for Patients with Metastatic Uveal Melanoma HLA A*02:01 Positive

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Study on Brain Activity in Treatment-Resistant Depression Using [18F]MC225 for Patients with Depression

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Study on the Effects of Tumor Removal in Patients with Metastatic Kidney Cancer Treated with Nivolumab and Ipilimumab Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Italy
  • Study on Cisplatin, Nab-paclitaxel, and Nivolumab with Radiotherapy for Patients with Non-Metastatic Muscle Invasive Bladder Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Italy
  • Study on the Effectiveness of Paclitaxel and Gemcitabine for Patients with Pancreatic Cancer Spread to the Abdomen

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Study Comparing Docetaxel and Androgen Receptor-Targeted Agents (Abiraterone or Enzalutamide) for Patients with Metastatic Castration-Resistant Prostate Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Italy